Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people

commented that icosapent ethyl might be used in secondary care but it would likely be used more in primary care. The committee concluded icosapent ethyl would likely be used mostly in a primary care setting. Population The population in the company's submission is narrower than the marketing authorisation in terms of LDL-C levels and is acceptable 3.4 Icosapent ethyl's marketing authorisation does not specify age or low- density lipoprotein cholesterol (LDL-C) thresholds (see section 2.1). However, the company only provided evidence for icosapent ethyl from the REDUCE-IT trial. This included people aged 45 and older who had cardiovascular disease, and people aged 50 and older who had diabetes and at least 1 other cardiovascular risk factor (see section 3.5). The trial also only included people with LDL-C levels above 1.04 mmol/litre and below or equal to 2.60 mmol/litre. A clinical expert noted that there are people younger than 45 who have cardiovascular disease and elevated fasting triglycerides in the NHS. They explained that many of these people have South Asian family backgrounds. The ERG commented that the treatment effect for icosapent ethyl varies by age, with a larger benefit observed in people under 65 (hazard ratio [HR] 0.65, 95% confidence
